Abbvie plans to lift $2 billion cap on deals - WSJ
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
AbbVie (ABBV) looks to new drugs to boost sales following Humira competition - WSJ
February 6, 2023 11:17 AM ESTAbbVie (NYSE: ABBV) is looking towards its new drugs to replace Humiria now that its blockbuster immune-disease therapy is facing lower-priced competition, the Wall Street Journal said Monday.
The WSJ said that the drugmaker's Chief Executive, Richard Gonzalez, revealed the company is turning to a pair of next-generation successors to reload the billions of dollars in sales that will be lost.
In... More
